Omar S Al-Kadi, Roa'a Al-Emaryeen, Sara Al-Nahhas, Isra'a Almallahi, Ruba Braik, Waleed Mahafza
{"title":"Empowering brain cancer diagnosis: harnessing artificial intelligence for advanced imaging insights.","authors":"Omar S Al-Kadi, Roa'a Al-Emaryeen, Sara Al-Nahhas, Isra'a Almallahi, Ruba Braik, Waleed Mahafza","doi":"10.1515/revneuro-2023-0115","DOIUrl":"10.1515/revneuro-2023-0115","url":null,"abstract":"<p><p>Artificial intelligence (AI) is increasingly being used in the medical field, specifically for brain cancer imaging. In this review, we explore how AI-powered medical imaging can impact the diagnosis, prognosis, and treatment of brain cancer. We discuss various AI techniques, including deep learning and causality learning, and their relevance. Additionally, we examine current applications that provide practical solutions for detecting, classifying, segmenting, and registering brain tumors. Although challenges such as data quality, availability, interpretability, transparency, and ethics persist, we emphasise the enormous potential of intelligent applications in standardising procedures and enhancing personalised treatment, leading to improved patient outcomes. Innovative AI solutions have the power to revolutionise neuro-oncology by enhancing the quality of routine clinical practice.</p>","PeriodicalId":49623,"journal":{"name":"Reviews in the Neurosciences","volume":" ","pages":"399-419"},"PeriodicalIF":3.4,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139643229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sona Mardanyan, Svetlana Sharoyan, Alvard Antonyan
{"title":"Diversity of amyloid beta peptide actions.","authors":"Sona Mardanyan, Svetlana Sharoyan, Alvard Antonyan","doi":"10.1515/revneuro-2023-0100","DOIUrl":"10.1515/revneuro-2023-0100","url":null,"abstract":"<p><p>Fibril formation by amyloidogenic proteins and peptides is considered the cause of a number of incurable diseases. One of the most known amyloid diseases is Alzheimer's disease (AD). Traditionally, amyloidogenic beta peptides Aβ40 and Aβ42 (Aβs) are considered as main causes of AD and the foremost targets in AD fight. The main efforts in pharmacology are aimed at reducing Aβs concentration to prevent their accumulation, aggregation, formation of senile plaques, neuronal death, and neurodegeneration. However, a number of publications have demonstrated certain beneficial physiological effects of Aβs. Simultaneously, it is indicated that the effects of Aβs turn into pathological due to the development of certain diseases in the body. The accumulation of C- and N-terminal truncated Aβs under diverse conditions is supposed to play a role in AD development. The significance of transformation of glutamate residue at positions 3 or 11 of Aβs catalyzed by glutaminyl cyclase making them more degradation resistant, hydrophobic, and prone to aggregation, as well as the participation of dipeptidyl peptidase IV in these transformations are discussed. The experimental data presented confirm the maintenance of physiological, nonaggregated state of Aβs by plant preparations. In conclusion, this review suggests that in the fight against AD, instead of removing Aβs, preference should be given to the treatment of common diseases. Glutaminyl cyclase and dipeptidyl peptidase IV can be considered as targets in AD treatment. Flavonoids and plant preparations that possess antiamyloidogenic propensity are proposed as beneficial neuroprotective, anticancer, and antidiabetic food additives.</p>","PeriodicalId":49623,"journal":{"name":"Reviews in the Neurosciences","volume":" ","pages":"387-398"},"PeriodicalIF":3.4,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David-Dimitris Chlorogiannis, Athina-Maria Aloizou, Theodoros Mavridis, Jonathan Andreas Sänger, Anargyros Chlorogiannis, Nikolaos Madouros, Panagiotis Papanagiotou
{"title":"Evolving frontiers: endovascular strategies for the treatment of delayed cerebral ischemia.","authors":"David-Dimitris Chlorogiannis, Athina-Maria Aloizou, Theodoros Mavridis, Jonathan Andreas Sänger, Anargyros Chlorogiannis, Nikolaos Madouros, Panagiotis Papanagiotou","doi":"10.1515/revneuro-2023-0148","DOIUrl":"10.1515/revneuro-2023-0148","url":null,"abstract":"<p><p>Cerebral vasospasm and delayed cerebral ischemia represent a very challenging aspect of cerebrovascular pathophysiology, most commonly subarachnoid hemorrhage, with significantly high mortality if left untreated. Considerable advances have been made in medical treatment and prompt diagnosis, while newer endovascular modalities have recently been proposed for cases of resistant cerebral vasospasm. However, there is still paucity of data regarding which and whether a single endovascular technique is non inferior to the pharmacological standard of care. In this review, we aim to summarize the current funds of knowledge concerning cerebral vasospasm and the emerging role of the endovascular techniques for its treatment.</p>","PeriodicalId":49623,"journal":{"name":"Reviews in the Neurosciences","volume":" ","pages":"463-472"},"PeriodicalIF":3.4,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139567643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alfredo Sanabria-Castro, Alberto Alape-Girón, Marietta Flores-Díaz, Ann Echeverri-McCandless, Alexander Parajeles-Vindas
{"title":"Oxidative stress involvement in the molecular pathogenesis and progression of multiple sclerosis: a literature review.","authors":"Alfredo Sanabria-Castro, Alberto Alape-Girón, Marietta Flores-Díaz, Ann Echeverri-McCandless, Alexander Parajeles-Vindas","doi":"10.1515/revneuro-2023-0091","DOIUrl":"10.1515/revneuro-2023-0091","url":null,"abstract":"<p><p>Multiple sclerosis (MS) is an autoimmune debilitating disease of the central nervous system caused by a mosaic of interactions between genetic predisposition and environmental factors. The pathological hallmarks of MS are chronic inflammation, demyelination, and neurodegeneration. Oxidative stress, a state of imbalance between the production of reactive species and antioxidant defense mechanisms, is considered one of the key contributors in the pathophysiology of MS. This review is a comprehensive overview of the cellular and molecular mechanisms by which oxidant species contribute to the initiation and progression of MS including mitochondrial dysfunction, disruption of various signaling pathways, and autoimmune response activation. The detrimental effects of oxidative stress on neurons, oligodendrocytes, and astrocytes, as well as the role of oxidants in promoting and perpetuating inflammation, demyelination, and axonal damage, are discussed. Finally, this review also points out the therapeutic potential of various synthetic antioxidants that must be evaluated in clinical trials in patients with MS.</p>","PeriodicalId":49623,"journal":{"name":"Reviews in the Neurosciences","volume":" ","pages":"355-371"},"PeriodicalIF":3.4,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zhaohui Song, Yuchuan Ding, Nathan Sim, Ho Jun Yun, Jing Feng, Pan Gu, Xiaokun Geng
{"title":"Vestibular function is associated with immune inflammatory response","authors":"Zhaohui Song, Yuchuan Ding, Nathan Sim, Ho Jun Yun, Jing Feng, Pan Gu, Xiaokun Geng","doi":"10.1515/revneuro-2023-0114","DOIUrl":"https://doi.org/10.1515/revneuro-2023-0114","url":null,"abstract":"Association between vestibular function and immune inflammatory response has garnered increasing interest. Immune responses can lead to anatomical or functional alterations of the vestibular system, and inflammatory reactions may impair hearing and balance. Vestibular disorders comprise a variety of conditions, such as vestibular neuritis, benign paroxysmal positional vertigo, Meniere’s disease, vestibular migraine, posterior circulation ischemia, and bilateral vestibular disease. Moreover, some patients with autoimmune diseases develop vestibulocochlear symptom. This paper offers an overview of prevalent vestibular diseases and discusses associations between vestibular dysfunction and immune diseases.","PeriodicalId":49623,"journal":{"name":"Reviews in the Neurosciences","volume":"59 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139071145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David-Dimitris Chlorogiannis, Athina-Maria Aloizou, Anargyros Chlorogiannis, Nefeli Kosta, Jonathan Andreas Sänger, Achilles Chatziioannou, Panagiotis Papanagiotou
{"title":"Exploring the latest findings on endovascular treatments for giant aneurysms: a review","authors":"David-Dimitris Chlorogiannis, Athina-Maria Aloizou, Anargyros Chlorogiannis, Nefeli Kosta, Jonathan Andreas Sänger, Achilles Chatziioannou, Panagiotis Papanagiotou","doi":"10.1515/revneuro-2023-0082","DOIUrl":"https://doi.org/10.1515/revneuro-2023-0082","url":null,"abstract":"Giant intracranial aneurysms represent a very challenging aspect of aneurysmal pathophysiology with very high mortality and morbidity if left untreated. Their variety in clinical presentation (subarachnoid hemorrhage, cranial nerve palsy, etc.) and pathological and imaging properties (location, anatomy, presence of collateral circulation) pose serious questions regarding the best treatment option. Admirable advances have been achieved in surgical techniques, while endovascular modalities with flow diversion techniques have become widely used. However, there is still lack of data regarding whether a single endovascular technique can be the universal treatment for such cases. In this review, we aim to summarize the current funds of knowledge concerning giant intracranial aneurysms and the role of endovascular management in their treatment.","PeriodicalId":49623,"journal":{"name":"Reviews in the Neurosciences","volume":"35 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139070967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Studying the Alzheimer’s disease continuum using EEG and fMRI in single-modality and multi-modality settings","authors":"Jing Li, Xin Li, Futao Chen, Weiping Li, Jiu Chen, Bing Zhang","doi":"10.1515/revneuro-2023-0098","DOIUrl":"https://doi.org/10.1515/revneuro-2023-0098","url":null,"abstract":"Alzheimer’s disease (AD) is a biological, clinical continuum that covers the preclinical, prodromal, and clinical phases of the disease. Early diagnosis and identification of the stages of Alzheimer’s disease (AD) are crucial in clinical practice. Ideally, biomarkers should reflect the underlying process (pathological or otherwise), be reproducible and non-invasive, and allow repeated measurements over time. However, the currently known biomarkers for AD are not suitable for differentiating the stages and predicting the trajectory of disease progression. Some objective parameters extracted using electroencephalography (EEG) and functional magnetic resonance imaging (fMRI) are widely applied to diagnose the stages of the AD continuum. While electroencephalography (EEG) has a high temporal resolution, fMRI has a high spatial resolution. Combined EEG and fMRI (EEG–fMRI) can overcome single-modality drawbacks and obtain multi-dimensional information simultaneously, and it can help explore the hemodynamic changes associated with the neural oscillations that occur during information processing. This technique has been used in the cognitive field in recent years. This review focuses on the different techniques available for studying the AD continuum, including EEG and fMRI in single-modality and multi-modality settings, and the possible future directions of AD diagnosis using EEG–fMRI.","PeriodicalId":49623,"journal":{"name":"Reviews in the Neurosciences","volume":"51 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139071239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"An overview of retinal light damage models for preclinical studies on age-related macular degeneration: identifying molecular hallmarks and therapeutic targets.","authors":"Giulia Carozza, Darin Zerti, Annamaria Tisi, Marco Ciancaglini, Mauro Maccarrone, Rita Maccarone","doi":"10.1515/revneuro-2023-0130","DOIUrl":"10.1515/revneuro-2023-0130","url":null,"abstract":"<p><p>Age-related macular degeneration (AMD) is a complex, multifactorial disease leading to progressive and irreversible retinal degeneration, whose pathogenesis has not been fully elucidated yet. Due to the complexity and to the multiple features of the disease, many efforts have been made to develop animal models which faithfully reproduce the overall AMD hallmarks or that are able to mimic the different AMD stages. In this context, light damage (LD) rodent models of AMD represent a suitable and reliable approach to mimic the different AMD forms (dry, wet and geographic atrophy) while maintaining the time-dependent progression of the disease. In this review, we comprehensively reported how the LD paradigms reproduce the main features of human AMD. We discuss the capability of these models to broaden the knowledge in AMD research, with a focus on the mechanisms and the molecular hallmarks underlying the pathogenesis of the disease. We also critically revise the remaining challenges and future directions for the use of LD models.</p>","PeriodicalId":49623,"journal":{"name":"Reviews in the Neurosciences","volume":" ","pages":"303-330"},"PeriodicalIF":3.4,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139058923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Serafina Perrone, Silvia Carloni, Valentina Giovanna Dell'Orto, Laura Filonzi, Virginia Beretta, Chiara Petrolini, Chiara Lembo, Giuseppe Buonocore, Susanna Esposito, Francesco Nonnis Marzano
{"title":"Hypoxic ischemic brain injury: animal models reveal new mechanisms of melatonin-mediated neuroprotection.","authors":"Serafina Perrone, Silvia Carloni, Valentina Giovanna Dell'Orto, Laura Filonzi, Virginia Beretta, Chiara Petrolini, Chiara Lembo, Giuseppe Buonocore, Susanna Esposito, Francesco Nonnis Marzano","doi":"10.1515/revneuro-2023-0126","DOIUrl":"10.1515/revneuro-2023-0126","url":null,"abstract":"<p><p>Oxidative stress (OS) and inflammation play a key role in the development of hypoxic-ischemic (H-I) induced brain damage. Following H-I, rapid neuronal death occurs during the acute phase of inflammation, and activation of the oxidant-antioxidant system contributes to the brain damage by activated microglia. So far, in an animal model of perinatal H-I, it was showed that neuroprostanes are present in all brain damaged areas, including the cerebral cortex, hippocampus and striatum. Based on the interplay between inflammation and OS, it was demonstrated in the same model that inflammation reduced brain sirtuin-1 expression and affected the expression of specific miRNAs. Moreover, through proteomic approach, an increased expression of genes and proteins in cerebral cortex synaptosomes has been revealed after induction of neonatal H-I. Administration of melatonin in the experimental treatment of brain damage and neurodegenerative diseases has produced promising therapeutic results. Melatonin protects against OS, contributes to reduce the generation of pro-inflammatory factors and promotes tissue regeneration and repair. Starting from the above cited aspects, this educational review aims to discuss the inflammatory and OS main pathways in H-I brain injury, focusing on the role of melatonin as neuroprotectant and providing current and emerging evidence.</p>","PeriodicalId":49623,"journal":{"name":"Reviews in the Neurosciences","volume":" ","pages":"331-339"},"PeriodicalIF":3.4,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139058924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qing-Hua Song, Ke-Xuan Zhao, Shuai Huang, Tong Chen, Ling He
{"title":"Escape from X-chromosome inactivation and sex differences in Alzheimer’s disease","authors":"Qing-Hua Song, Ke-Xuan Zhao, Shuai Huang, Tong Chen, Ling He","doi":"10.1515/revneuro-2023-0108","DOIUrl":"https://doi.org/10.1515/revneuro-2023-0108","url":null,"abstract":"Sex differences exist in the onset and progression of Alzheimer’s disease. Globally, women have a higher prevalence, while men with Alzheimer’s disease experience earlier mortality and more pronounced cognitive decline than women. The cause of sex differences in Alzheimer’s disease remains unclear. Accumulating evidence suggests the potential role of X-linked genetic factors in the sex difference of Alzheimer’s disease (AD). During embryogenesis, a remarkable process known as X-chromosome inactivation (XCI) occurs in females, leading to one of the X chromosomes undergoing transcriptional inactivation, which balances the effects of two X chromosomes in females. Nevertheless, certain genes exceptionally escape from XCI, which provides a basis for dual expression dosage of specific genes in females. Based on recent research findings, we explore key escape genes and their potential therapeutic use associated with Alzheimer’s disease. Also, we discuss their possible role in driving the sex differences in Alzheimer’s disease. This will provide new perspectives for precision medicine and gender-specific treatment of AD.","PeriodicalId":49623,"journal":{"name":"Reviews in the Neurosciences","volume":"194 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139070968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}